On April 3rd 2024, the New England Journal of Medicine published results of a Phase 2 clinical trial of the diabetes drug lixisenatide. They were testing whether this medication could possibly help to slow down progression of PD. This clinical trial was testing the class of drugs known as GLP-1 receptor agonists. It showed mixed results - some promising, some needing further investigation. These findings have sparked a great deal of discussion, even appearing in The New York Times. Lixisenatide is still considered to be experimental for Parkinson’s and more research is required before it could potentially become part of a treatment regimen. There are currently no GLP-1 receptor agonists, including lixisenatide, that are approved for use in Parkinson’s, though studies continue to investigate the potential. Read more at the link below.
Comments